NRAA responds to proposed $1 cut in EPO reimbursement.
D016527:Drug Costs; D000068817:Epoetin Alfa; D004921:Erythropoietin / Q000191:economics*; D006270:Health Facility Administrators; D006397:Hematinics / Q000191:economics*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000188:drug therapy*; D006278:Medicare / Q000191:economics*; D011994:Recombinant Proteins; D012051:Reimbursement Mechanisms / Q000191:economics*; D012958:Societies, Scientific; D014481:United States
D006397:Hematinics; D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa